Pipeline Biotech

Home | Pipeline. The coronavirus-induced selling in the markets is exposing great opportunities in the biotech space. compensation for a genetically determined lack of the respective enzyme by regular infusion of biotechnologically produced substitute. Our Pipeline We aspire to be a dynamic R&D organization by focusing on the best science for those therapies that can deliver true innovation for patients. We are exploring a range of versatile tools and cell types in pursuit of a truly "off-the-shelf" cell therapy. We are advancing our pipeline of antibodies with best-in-class profiles for the treatment of patients with cancer. New MS Therapy Company, Pipeline, to Focus on Rejuvenating Coating That Protects Nerve Cells. We designed KSI-301 with the goal to keep the disease under control for longer, aiming to dose as infrequently as every 3, 4, or. Phase 1 Phase in progress. And that time could be coming. 11975 El Camino Real, Suite 300 San Diego, CA 92130 T (858) 222-8041 F (858) 436-8155. OX40 selected based on superiority vs. Oncorus Appoints Mary Kay Fenton to its Board of Directors. is a clinical-stage biopharmaceutical company exploring new ways to treat dermatological and gastrointestinal diseases, including alternatives to topical steroids. Lupin's Biotech facility is spread over 22,000 square meters at Pune, India. IL-15 plays multiple roles in the immune system by controlling the homeostasis and activation of T, B, NK and. CSL Behring is a global leader in developing and delivering high quality medicines that treat people with rare and serious diseases. Through agreements with Cytune Pharma,. SEE OUR APPROACH. ONY Biotech is currently involved in a pivotal trial for an aerosolized surfactant therapy that we call InfasurfAero. Phase 2, PDUFA date). Amgen and the Amgen Foundation inspire the next generation of innovators by funding science education programs at every level, from local high schools to the world’s premier educational institutions. (ADP‑A2M4CD8) Multiple solid tumors**. VP, Global Commercial Strategy - Early Pipeline Head | BOSTON | Top Rare Disease Commercial-Stage Biotech | RETAINED SEARCH. Our Pipeline We aspire to be a dynamic R&D organization by focusing on the best science for those therapies that can deliver true innovation for patients. Passion for Discovery pipeline. Each of our programs strictly follows the principles of our R&D strategy: Selecting targets that are genetically linked to the. 3 Biotech Pipeline Areas To Keep An Eye On In 2018 Although there are still a few days left for the year to end, 2017 has turned out to be pretty good for the pharma and biotech sector where FDA. Allogeneic or Autologous Additional AAC Applications Solid & Liquid Tumors. , our leading cell therapy pipeline now includes investigational cell therapies and next-generation technologies for a range of hematologic malignancies and solid tumors. View our financial calendar and what conferences, meetings and congresses we will visit in 2019 on our upcoming events page. Other drugs in the 2019 development pipeline have seemingly met their maker, only to yield positive data that clears a path forward. Pipeline Timmune In 2015, Beike founded Timmune to develop what now comprises of cell therapies and fusion protein molecule drugs based on proprietary MAR and TriTE technology. Pipeline We are a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Our unique platform has delivered a clinical stage, multi-drug, multi-target pipeline. ; 2 CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib and fisogatinib in Mainland China, Hong Kong, Macau and Taiwan. , GILD is all set to acquire immuno-oncology company, Forty Seven. AXIM Biotech Offers the Broadest Pipeline in the Cannabis Industry -- SECFilings. We are delighted that the LentiBOOST™ technology may help Beam further enhance the clinical success of its CAR-T pipeline. com April 16, 2019 07:35 AM Eastern Daylight Time. Captisol, Ligand's most prominent. Immuno-Oncology. Partnered with AstraZeneca. Pointing to its most advanced pipeline candidate, BDTX-189, which is currently in a Phase 1/2. The p38 kinase inhibitors represent a platform for the treatment of various inflammatory and age-related diseases. Based on innovative material science and composition-of-matter patents, Xbio ™ Technology has limitless potential to have a far-reaching and positive impact across all human and animal health care and support the global drive to reduce the threat of antimicrobial resistance caused by biofilms. The Company’s pipeline features development programs in rare diseases associated with growth hormone deficiencies. MorphoSys mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. With this goal in mind, we created unique and cutting-edge technologies to reprogram and stimulate the immune system. BNT111 is developed for the treatment of advanced melanoma in patients with metastatic tumors and as an adjuvant treatment after tumor resection. Evaxion is building a unique pipeline of immunotherapies and vaccines addressing two of the biggest health threats worldwide Utilizing superior delivery technologies, we are rapidly expanding our preclinical pipeline and manifesting the ground-breaking potential of our immuno-oncology platform, PIONEER. Pipeline Contact We are a dedicated team of research and medical experts leading the clinical advancement of HemaMax as the ideal combination immunotherapeutic for the successful treatment of cancer. Phone: +1 (212) 967-4077. 6 AskGene and Aosaikang submit the IND package of ASK965 to CFDA. ARTHEX BIOTECH. Development Pipeline Robust pipeline with potentially disruptive technologies. Are they re­al­ly need­ed? UP­DAT­ED: Gilead — Piv­otal Covid-19 study of remde­sivir ‘met its pri­ma­ry end. Summary: Cornerstone Search Group has been retained by a top. The depth and versatility of our RNAi technologies enable us to address conditions in virtually any therapeutic area and pursue disease targets that are not otherwise. Many roots of organic chemistry, and of medicinal chemistry in particular, often originate in what might seem like an unlikely place: the dyestuff industry of the late 19th century. One-time, AAV-based gene therapy for patients with Sanfilippo syndrome type B (MPS IIIB). We work for major European pharma and biotech companies. We are seeking energetic and hard working professionals to join our growing team. com Address:101 Hudson Street, Suite 2100 Jersey City, NJ 07302 USA Tel:1-201-6336433 Fax:1-201-633-6428. Click to read more on JHL1152 (Ipilimumab). Based on innovative material science and composition-of-matter patents, Xbio ™ Technology has limitless potential to have a far-reaching and positive impact across all human and animal health care and support the global drive to reduce the threat of antimicrobial resistance caused by biofilms. is a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with various conditions. 5 Million Series B Financing Co-Led by Cowen Healthcare Investments and Perceptive Advisors. 15A, Alexandria Innovation Centre AKP, Genome Valley, Shameerpet Hyderabad, Telangana 500078 Products / Pipeline . Phase 1 Phase 2 Phase 3 Submitted Approved. For patients in the U. View our financial calendar and what conferences, meetings and congresses we will visit in 2019 on our upcoming events page. The biopharmaceutical industry’s positive regulatory momentum carried on through 2019, despite an early-year government shutdown, a data manipulation scandal around a high-profile approval, and. Lacutamab / IPH4102. Diversified Dermatology-Focused Pipeline with Near Term Milestones Safety and efficacy of these investigational products have not been established. Our goal is to revolutionize how the life sciences industry explores, examines, assesses and manipulates cells, drugs and toxins. and Europe: Respivant Sciences: RVT-1601: idiopathic pulmonary fibrosis (IPF) Phase IIb trial initiated enrolling 180 subjects in the U. Discovery Pipeline. Activities. Initial results from a Phase 1. The $50 million payment is a small price to pay to help boost its paltry pipeline. At Novo Nordisk, our R&D pipeline reflects our long-standing commitment to driving change to defeat diabetes and other serious chronic conditions. Alexion Pharmaceuticals (ALXN, $105. New data indicates that glycoprotein D acts as a decoy, so the. Therapeutic Areas > The Technology Driving Our Pipeline. The project portfolio comprises small, orally active immunomodulatory molecules as well as antibody-based immunotherapy. Minerva Neurosciences is focused on the central nervous system (CNS) disease pharmaceutical market. Karyopharm's drug pipeline includes 4 unique investigational medicines targeting both hematologic and solid tumor malignancies. Summary: Cornerstone Search Group has been retained by a top. Gastro-Intestinal Cancer. Our second approved product, first-in-class CD38 antibody. Medical Innovation and R&D are at the core of the Celgene philosophy for building life-changing treatments and therapies. VAL-083 Shows Potential Against Multiple Cancers. Pipeline Timmune In 2015, Beike founded Timmune to develop what now comprises of cell therapies and fusion protein molecule drugs based on proprietary MAR and TriTE technology. Investment Thesis and Portfolio Focus: Investment across the biotech space (large and small) often sees a significant amount of risk associated with pipeline success and timelines. Agios has leveraged its core capabilities in cellular metabolism and precision medicine to build a product engine that is focused in the therapeutic areas of cancer and rare genetic diseases. Bharat Biotech is a pioneering biotechnology company known for its world-class R&D and manufacturing capabilities. Our mission is to develop intravenous (IV) tramadol, a potential alternative that could reduce the use of conventional opioids, for patients suffering from acute pain in the U. From modest beginnings 20 years ago, Neem Biotech has come of age. The biotech sector was in focus with new drug approvals, acquisitions and regular pipeline updates from quite a few companies. Richard Chang, a Hong Kong-based lawyer with international law firm Goodwin Procter active in advising life sciences firms on IPO preparations, said the Hong Kong biotech deals pipeline is. ALXN has developed a comprehensive pipeline of therapies for ailments such as: Paroxysmal. Atreca, Inc. Diversified Dermatology-Focused Pipeline with Near Term Milestones Safety and efficacy of these investigational products have not been established. These diseases often involve autoreactive T cells and B cells, which communicate through shared biological pathways. The programs in our broader Synerlytic™ platform serve as the backbone of Virogin’s continued R&D of targeted and improved cancer. Fabry Disease. The safety and optimal dose selection of armored HPVSTs in combination with an anti-PD-1 antibody is currently being evaluated in an ongoing investigator. Atara Biotherapeutics's robust, late-stage pipeline features a host of potentially transformative T-cell immunotherapies for cancer, autoimmune and viral diseases. Actinium is developing a pipeline of Antibody Radiation Conjugates for targeted conditioning and combination therapies. CSA BioTech is a clinical stage firm developing Ceragenins: powerful, first in class, small molecules with broad application uses. The steady growing, ~$4B* Japanese diabetes market offers a unique value creation opportunity. is a Winnipeg, Canada, based new drug discovery and development company, concentrating on new treatments for cancer. Reata is focused on developing novel therapies for life threatening diseases that have few or no treatment options… Nrf2 activators exhibit broad, anti-inflammatory, anti-fibrotic, and promitochondrial activity in vitro and. Many roots of organic chemistry, and of medicinal chemistry in particular, often originate in what might seem like an unlikely place: the dyestuff industry of the late 19th century. Delivering the promise of healthier lives™ Our products fall into two categories: nutraceuticals (dietary supplements) and pharmaceutical medicines. Our mission is to deliver affordable, safe and high-quality vaccines and bio-therapeutics that help people prevail over diseases. Our antibodies are being evaluated in numerous clinical studies. For decades there have been no new effective treatment options for the disorders Edesa is addressing. RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with HAE. Pivotal Study Start - 2H 2020. Our Pipeline Cadent Therapeutics has developed a strong pipeline of medicines for movement, mood, and cognitive disorders, with candidates rapidly advancing into the clinic. CERC-002 CERC-005 CERC-006 CERC-007 CERC. We employ biologic and small molecule-based approaches that are designed to enhance the ability of the patient's own immune system to detect and destroy cancer cells. Biotech companies are only as good as their pipeline. Editing cells inside the body to treat genetically-defined diseases. Development Pipeline Our Team Management Team Board of Directors Advisory Board Contact Us. Tel: 914-762-7586 Email: [email protected] Pharmaceutical Pipeline. New data indicates that glycoprotein D acts as a decoy, so the. Gilead is advancing a pipeline of cancer therapies in the areas of cell therapy, immuno-oncology and targeted therapies. F-star’s leadership team has decades of combined experience from holding senior-level positions in both pharma and biotech and involving the development of dozens of biologics from. Expanding the pipeline beyond RUCONEST®: With validation secured from the approval of the first product from our transgenic platform, we will now seek to initiate new projects on this platform. biotech-pipeline. Our scientists are currently working on novel and innovative treatments to address the unmet needs of people living with diabetes, obesity, haemophilia, growth disorders and non-alcoholic. EDP Biotech Corporation is a privately held medical device company focused on the development and commercialization of immunodiagnostic tests. Headquarter/4F, No. Download CRISPR Therapeutics Corporate Presentation. Now SIRION offers one of the world’s most comprehensive viral vector technology platforms based on lenti-, adeno-, and adeno-associated viruses which expedites gene therapy research and advances. Mirati Therapeutics Reports Year-End 2019 Financial Results And Recent Corporate Updates 02/19/2020 Mirati Therapeutics, Inc. Pipeline admin 2020-02-26T12:21:29-05:00 Product Pipeline Alimera Sciences, Inc. DM1 symptoms affect mainly the nervous system, the heart, and the skeletal musculature, although other alterations in other systems or organs are also reported. Disruption of this protein interaction can trigger the elimination of senescent cells. At Reata Pharmaceuticals, our mission is to develop innovative therapies that change patients’ lives for the better. Reata is focused on developing novel therapies for life threatening diseases that have few or no treatment options… Nrf2 activators exhibit broad, anti-inflammatory, anti-fibrotic, and promitochondrial activity in vitro and. For a drug or program to be shown on the pipeline, it must meet certain conditions. Stealth BioTherapeutics continues to expand our broad knowledge of mitochondrial biology and novel chemistries, enabling us to advance our mitochondrial platform of late-stage clinical programs and pipeline candidates. Our current programs are investigating applications across multiple therapeutic areas—starting with rare enzyme deficiencies, cancer and autoimmune diseases. Meet our well known leadership team and biotechnology entrepreneurs and learn about. Hurler Syndrome. 450 Seventh Avenue,Suite 1607, New York, NY 10123. Currently, a year-long course of pegylated interferon-alpha is the best available curative therapy and it has a low functional cure rate of approximately 3-7%. our mission at Oncorus. REDONDO BEACH, CA--(Marketwired - Feb 15, 2017) - SECFilings. Learn about Alnylam's pipeline of investigational RNAi therapeutics and how the company is leading the translation of RNAi into a new class of innovative medicines to treat a variety of conditions. Get Marker News Delivered To Your Inbox. Inhibiting the Inflammation Cascade. Making drug targets functional and stable is of utmost importance in the drug discovery and development process. T he easiest way to peek inside the inner workings of a brand-new biotech company? Check out its pipeline. The mysterious coronavirus outbreak in the Chinese city Wuhan, now termed as COVID-19, and its fast spread to many other countries, endangers thousands of lives. It also focuses on the risk-adjusted NPV valuation methodology, portfolios of multiple drug candidates, and how value is impacted by the characteristics of the investor or acquirer. SMSbiotech Product Pipeline. When possible I include PDF version to provide a historical record. Tiba is a Boston based pre-clinical biotechnology company with a mission to create a new generation of vaccines and immunotherapies for human and animal disease. We are skilled in producing Aspart, Biosimilars, Immunosuppresants and Lispro. With 68,000+ drug profiles including 15,000 drugs in active development, it's the go-to resource for preclinical, clinical, and pipeline coverage, and lifecycle management tracking. What started out with R&D around a Neem tree and its medicinal purposes has grown to drug development for rare diseases and chronic lifestyle diseases. Pipeline Overview Clinical Development Program ALS Progressive MS Publications Pipeline PIPELINE OVERVIEW There is significant unmet need for effective therapies for those people whose lives are disrupted by highly debilitating and often fatal neurodegenerative diseases. Flu Prevention & Treatment. Many roots of organic chemistry, and of medicinal chemistry in particular, often originate in what might seem like an unlikely place: the dyestuff industry of the late 19th century. Developing life more humann. Breast, ovarian and endometrial cancers. Here’s a look: Vertex’s VX-659 + Tezacaftor + Ivacaftor. The mission of the Epilepsy Foundation includes accelerating new therapies for people living with epilepsy and seizures. NeuroInitiative: BioTech to Cure Disease | Find out how we're using neuro-simulation to help find a cure Parkinson's Disease. * Full pipeline not shown ** NYCE- New York CRISPR-edited ***In. According to Pierluigi Paracchi, CEO of the Italian biotech Genenta Science, biotechs in Europe are also feeling the strain. Pieris is developing a diversified pipeline of inhaled Anticalin® molecules to locally address respiratory disease via inhalation and has established a transformative collaboration with AstraZeneca to access industry-leading formulation and device capabilities and accelerate the time to market of these drug candidates. 580 White Plains Road Suite 210 Tarrytown, NY 10591. But what the biotech does have could be game-changers. Hydrocarbon Multi Clean - Pipeline Remediation and Flow Assurance Solution. The coronavirus-induced selling in the markets is exposing great opportunities in the biotech space. Multiple Sclerosis (MS) is a debilitating autoimmune disease affecting an estimated one million people in the U. Currently, our scientists are working closely with partners at the University at Buffalo to develop acellular tissue engineered vessels as well as hydrogen detectors. Galapagos is progressing one of the largest pipelines in biotech, with a broad range of disease areas being explored in Phase 2 and Phase 3 with filgotinib, Phase 3 with '1690 and Phase 2 with '1205 in IPF, multiple Phase 1 and Phase 2 studies with other clinical programs, and >20 discovery programs. Our primary objective is the development of innovative therapies based on the principle that our immune system can be “instructed” to recognize the tumor and reject it as a foreign entity. Gastro-Intestinal Cancer. I-Mab Biopharma Co. Lupin's Biotech facility is spread over 22,000 square meters at Pune, India. The biotech sector was in focus with pipeline updates from a few small biotech companies. Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families. Biogen BIIB has entered into a collaboration deal with Sangamo SGMO. We are a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Our foundation is built on our. Biogen BIIB has entered into a collaboration deal with Sangamo SGMO. Spinocerebellar Ataxia Program SCA is a genetic, degenerative neurological condition that affects approximately. Turning scientific discovery into patient. We are advancing a pipeline of investigational therapies for a wide range of conditions linked to a disrupted microbiome, starting with recurrent C. GECCO offers a unique collection of cofactors. The pipeline of SOM Biotech mainly contains programs focused on Orphan indications. ADZ4 combines the virus backbone of ADZ1 with the expression of CD137 ligand (4-1BBL). Each of our programs strictly follows the principles of our R&D strategy: Selecting targets that are genetically linked to the disease, engineering our molecules to cross the blood-brain barrier, and guiding clinical development through the discovery and use of biomarkers. We are a commercial stage biopharmaceutical company, focused on the development of products that address the medical challenges in. More than 130 sponsors have repeatedly used our services during the last ten years. Our mission is to deliver affordable, safe and high-quality vaccines and bio-therapeutics that help people prevail over diseases. (Nasdaq: KIN). Evaxion is building a unique pipeline of immunotherapies and vaccines addressing two of the biggest health threats worldwide Utilizing superior delivery technologies, we are rapidly expanding our preclinical pipeline and manifesting the ground-breaking potential of our immuno-oncology platform, PIONEER. Theseproblemsareafarcryfromthe situation in theearlydaysofbiotech-whenthefirstbiotechdrug-EliLilly's l recombinanthumaninsulin-was ap-B provedin 1982inarecord5 months. Spanish Biotech Pipeline This website contains the latest developments in health, agrofood and industrial biotechnology fields, by members of ASEBIO. Pipeline Expansion. Lysosomal Function. MORE ABOUT SQZ AACs. Replimune is executing a broad, aggressive development plan with a pipeline of potent oncolytic immunotherapies now entering clinical studies for multiple types of cancer. SMALL MOLECULES VIRAL VECTOR POWERED THERAPEUTICS Geneva Biotech is a privately held biotechnology company, based in Geneva, Switzerland. The pipeline of SOM Biotech mainly contains programs focused on Orphan indications. NKX101: NKG2D activating receptor, OX40 costimulatory domain, CD3ζ signaling moiety, membrane bound IL-15. InCarda is developing a new therapy for patients with acute episodes of Atrial Fibrillation. Using “Molecular Glues” to Hijack the Body’s Garbage Disposal System. Reata's pipeline also includes RTA 901, which has shown favorable activity in a range of preclinical models of neurodegeneration and neuroprotection, including diabetic neuropathy and neural inflammation. For the biotech firms (ALXN, AMGN, BIIB, CELG, GILD, REGN, and VRTX), Goldman estimates that by 2020 these companies will be generating $32 billion from the pipeline on top of a base revenue of. Our therapeutic candidate KSI-301, currently in clinical development, is a novel anti-VEGF biologic designed to have extended ocular half-life, high potency and high ocular tissue bioavailability and biocompatibility. In addition, FAR Biotech is has developed quantum models in other established targets such as tumor suppressor gene p53, the focal adhesion kinase 1 (FADK1), polo-like kinase (PLK1), human epidermal growth factor receptor (Her2 kinase), mammalian target. Aiming to treat β-thalassemia and sickle cell disease with gene-edited hematopoietic stem cells. Tel: 914-762-7586 Email: [email protected] T he easiest way to peek inside the inner workings of a brand-new biotech company? Check out its pipeline. In November 2009, Agennix AG acquired GPC Biotech. The coronavirus-induced selling in the markets is exposing great opportunities in the biotech space. Under his leadership, J&J built a strong pipeline of metabolic assets ranging from discovery stage programs to clinical assets. The preclinical, clinical and production process of gp-ASIT+ TM for. Many roots of organic chemistry, and of medicinal chemistry in particular, often originate in what might seem like an unlikely place: the dyestuff industry of the late 19th century. is a Bristol-Myers Squibb company. A cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody. Our pipeline of key proprietary products includes a late-stage drug candidate for the treatment of schizophrenia and the treatment of bipolar I disorder, and an early-stage drug candidate in immuno-oncology. Bharat Biotech is a pioneering biotechnology company known for its world-class R&D and manufacturing capabilities. CALY-002 the lead program of Calypso Biotech, is a best-in-class humanized monoclonal antibody inhibiting Interleukin-15 (IL-15). Streamline Your Research with Intuitive Analytics. AXIM Biotech Offers the Broadest Pipeline in the Cannabis Industry -- SECFilings. 2155 Park Boulevard Palo Alto, CA 94306. Our pipeline programs are in Fibrosis (Collagen type I translation inhibitors), RSV (inhibiting the production of viral proteins by host cell ribosomes), Oncology (C-Myc translation inhibitors), Huntington's Disease (monitoring mutant Huntingtin translation pausing) and Repeat Associated Diseases (translation malfunctions). Now SIRION offers one of the world’s most comprehensive viral vector technology platforms based on lenti-, adeno-, and adeno-associated viruses which expedites gene therapy research and advances. Our pipeline programs are in Fibrosis (Collagen type I translation inhibitors), RSV (inhibiting the production of viral proteins by host cell ribosomes), Oncology (C-Myc translation inhibitors), Huntington’s Disease (monitoring mutant Huntingtin translation pausing) and Repeat Associated Diseases (translation malfunctions). Visit our Product Pipeline, learn about clinical trials, and discover the medical research and development that Celgene puts into every therapy, service, and product. Discovery Phase complete. OX40 selected based on superiority vs. Emerging Biotech Environmental Testing Healthcare Pipeline. With eight offices staffed with dedicated scientists throughout China, the Company has amassed the largest compound portfolio covering all major therapeutic areas. “Actualidad Economica” is the dean magazine of the Spanish economic press, founded in 1958. Corporate Filings. read more > Adaptimmune Shares Triple as SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications. FDA Grants Priority Review for Kite’s KTE-X19 Biologics License Application. (Biosimilar Ipilimumab) Late-Stage Melanoma. is a biotech company seeking to find treatments and cures for Sanfilippo Syndrome. Target: AXL receptor tyrosine kinase (AXL) ATI-501 & 502 - Aclaris. Get a brief summary of the day’s biotech price and volume movers and accompanying news. Our ambition is prevention and cure. SapVax is developing a suite of first-in-class cancer vaccines based on a novel self-adjuvanting peptide platform technology for immuno-oncology applications. The pipeline additions include Amgen's Proliva ® and Xgena ® (denosumab), and the PD-1 and PD-L1 "checkpoint inhibitors. CAR-T therapy has delivered some stunning results against blood cancers but,. is a Winnipeg, Canada, based new drug discovery and development company, concentrating on new treatments for cancer. Arcturus’ versatile RNA therapeutics platform can be applied toward all types of RNA medicines including small interfering RNA, messenger RNA, antisense RNA, microRNA and gene editing. SMALL MOLECULES VIRAL VECTOR POWERED THERAPEUTICS Geneva Biotech is a privately held biotechnology company, based in Geneva, Switzerland. Using the NurOwn® technology platform, BrainStorm is focused on realizing the potential of life-changing autologous cellular…. Preclinical Phase complete. Search Pipeline. All content is Derek's own, and he does not in any way speak for his employer. Merck KGaA, Darmstadt, Germany, which operates this website, uses the firm name "Merck KGaA, Darmstadt, Germany," in the United States and Canada, and also uses "EMD Serono" in healthcare, "MilliporeSigma" in life science and "EMD Performance Materials" in the performance materials business. Rubius Therapeutics is advancing a broad pipeline of RCT™ product candidates. , Suite 318 Hagerstown, MD 21740 USA. We designed KSI-301 with the goal to keep the disease under control for longer, aiming to dose as infrequently as every 3, 4, or. Our Pipeline of Immune Modulators and Precision Therapies for Multiple Solid Tumors Address Patient Populations in Need of Better Cancer Therapies. The mission of the Epilepsy Foundation includes accelerating new therapies for people living with epilepsy and seizures. View our financial calendar and what conferences, meetings and congresses we will visit in 2019 on our upcoming events page. Maverick’s highly innovative platform, COBRA™, is the most advanced bispecific T-cell engaging platform in its class, designed to safely target solid tumors with highly specific and potent activity. Although there are still a few days left for the year to end, 2017 has turned out to be pretty good for the pharma and biotech sector where FDA approvals are concerned. Gastro-Intestinal Cancer. Our current clinical studies are designed to further evaluate the safety and efficacy of our sPLA2 inhibitor technology. Clinical Trials. Our areas of focus are a result of many years of experience and a deep understanding of industry dynamics and the leadership positions that the principals have established in these areas. These new medicines have the potential to significantly improve immune response in patients with these conditions. As the earnings season comes to an end, the focus is back on pipeline updates from biotech players. Pharmaceutical companies usually have a number of compounds in their pipelines. Research and development is a coordinated global function at Santen, and our R&D strategy is built on a dual approach: (1) leveraging our company’s decades of experience in ophthalmology and clinical trials undertaken in many regions of. Zairi is a founder and Managing Director of the Mendham Investment Group (MIG). Alexion Pharmaceuticals (ALXN, $105. Our pipeline includes one drug candidate and several compounds in different stages of pre-clinical study. ARWR Due Diligence. New MS Therapy Company, Pipeline, to Focus on Rejuvenating Coating That Protects Nerve Cells. Biotech Stock Roundup: MRNA Surges, Pipeline Updates from INCY, HRTX & NGM Bio - February 26, 2020 - Zacks. Learn about Alnylam's pipeline of investigational RNAi therapeutics and how the company is leading the translation of RNAi into a new class of innovative medicines to treat a variety of conditions. ReviveMed's Pipeline of Metabolic Diseases We are initially focused on discovering therapeutics for alcoholic and non-alcoholic fatty liver diseases. The FDA's flexibility and focus on marketplace. PARTNER TERRITORY; TTP399 (GKA) Type 1 Diabetes. Petrobras has started to design a gas pipeline network expansion plan with investments of more than 1 billion US$ for its system alone, including new gas. Previously Juvenescence AI limited, Generait was founded in July 2017, a partnership between Juvenescence and the leading AI drug discovery company Insilico Medicine, Inc, providing a vehicle to develop promising candidates identified using its end-to-end automated drug discovery pipeline through to clinical proof of concept. Pipeline Timmune In 2015, Beike founded Timmune to develop what now comprises of cell therapies and fusion protein molecule drugs based on proprietary MAR and TriTE technology. Upon closing, XBiotech was paid $750 million upfront with $75 million held in escrow for 18 months. The biotech sector was in focus with new drug approvals, acquisitions and regular pipeline updates from quite a few companies. OUR PIPELINE & SCIENCE Led by scientists with an elite level track record in biomedical research, we are advancing a pipeline of novel and proprietary drug candidates by applying our unique platform technologies. Scientific Publications. Utilizing our proprietary discovery platform, we are developing highly selective small molecules that are designed to modulate the critical immune responses underlying these diseases. KindredBio is a leading veterinary biopharmaceutical company developing innovative medicines for cats, dogs, and horses. To create Infasurf ® (calfactant), we start by sourcing the high-quality components that are put through rigorous testing. Pipeline Our macrocyclic platform has fueled our pipeline of highly potent, proprietary kinase inhibitors that are structurally different from many existing kinase inhibitors and may address the key issues of emerging treatment resistance and toxicities that limit duration of treatment. Our medicines and vaccines in development are classified into three stages: phase I, phase II and phase III. Allogeneic or Autologous Additional AAC Applications Solid & Liquid Tumors. Traditionally, as a former division of a large multinational pharmaceutical company, the R&D unit had several areas of interest, with three main areas of expertise for the discovery and development of drug candidates: rheumatology, gastroenterology, and gynaecology. Type and Press “enter” to Search. However, that does not mean you should include them all in your valuation. MORE ABOUT SQZ AACs. We are focused on the rapid design and development of precision therapies for people with cancer and rare diseases. , which holds 14,943,650 shares of common stock and 500,000 shares of preferred stock representing 45. Manufacturing at The Elisa Linton Center for Rare Disease Therapies. 30) is one of several biotech stocks that specialize in rare diseases. CCM is defined as a collection of small blood vessels in the brain — malformations — that are enlarged and irregular and can lead to altered blood flow. Get Important News and Updates by Email Subscribe. Tackling a range of diseases with different approaches. is a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with various conditions. Product Pipeline SBI Biotech strives for novel drug development targeting cancers and autoimmune diseases. Current R&D Pipeline Vaccines are considered the most effective tool to prevent the infectious diseases. to fund the advance of a pipeline spearheaded by Johnson & Johnson-partnered anti-BCMA JNJ-4528. Asceneuron SA Asceneuron is an emerging biotech company excelling in the discovery and development of ground breaking therapeutics for neurodegenerative disorders with high unmet medical need such as orphan tauopathies, Alzheimer’s and Parkinson’s diseases. PDUFA date, Advisory Committee Meetings). Legend Biotech is a multinational biopharmaceutical company focused on discovering and developing cutting-edge cell-based therapies with the ultimate goal of changing the way life-threatening diseases are treated. Acticor Biotech is a biopharmaceutical company, founded in 2013 as a spin-off of Inserm (Paris, France), developing an innovative drug for the treatment in the acute phase of ischemic stroke. The biopharmaceutical industry’s positive regulatory momentum carried on through 2019, despite an early-year government shutdown, a data manipulation scandal around a high-profile approval, and. More than 130 sponsors have repeatedly used our services during the last ten years. Pipeline Therapeutics is located near the University of California, San Diego and many of Southern California's finest beaches. Our rich pipeline of innovative drugs, with over 15 indications, is designed to address significant unmet medical needs. Daily Biotech Price Movers & Pipeline Updates. Rubius Therapeutics is advancing a broad pipeline of RCT™ product candidates. • PPD Pipeline involves network of tasks, many following fixed task precedence relationships • Key decisions elements: – Selection of projects & termination of projects – Sequencing, scheduling, resource assignments – Selection of hedging strategies • Key complicating issues: failure / termination of projects • Conventional approaches. Executing an open innovation model: Cooperation is key to competition for biopharmaceutical companies 3 What is open innovation? Companies use OI to source external knowledge, ideas, resources, and technologies. April 23, 2020, Interim report. Our primary objective is the development of innovative therapies based on the principle that our immune system can be “instructed” to recognize the tumor and reject it as a foreign entity. Therapeutic Areas > The Technology Driving Our Pipeline. Multiple Sclerosis (MS) is a debilitating autoimmune disease affecting an estimated one million people in the U. Shuwen Biotech Co Ltd - Product Pipeline Analysis, 2019 Update Summary Shuwen Biotech Co Ltd (Shuwen Biotech) operates as a medical equipment company. * UCD is a serious and life-threatening inherited, rare genetic disease caused by a deficiency in one of the six enzymes or two. Pipeline Therapeutics is located near the University of California, San Diego and many of Southern California's finest beaches. Regeneron (NASDAQ: REGN) is a leading science and technology company delivering life-transforming medicines for serious diseases. With a focus on minimising disease burden and antimicrobial resistance, our ethos is to do things differently. Our Pipeline We aspire to be a dynamic R&D organization by focusing on the best science for those therapies that can deliver true innovation for patients. We are skilled in producing Aspart, Biosimilars, Immunosuppresants and Lispro. And thanks to the commitment of the R&D unit, different successful products were developed in these therapeutic areas. European therapeutics vaccines monoclonal antibodies biologics biocomparables generics follow-on proteins 505(b)2 approvals FDA EMEA EMA. The word pipeline in biotech companies generally refers to the stages of clinical trials. Email: [email protected] X4's pipeline is comprised of first-in-class, oral, small molecule antagonists of chemokine receptor CXCR4, which have the potential to treat a broad range of rare diseases, including primary immunodeficiencies (PIs) and cancer. TAVALISSE (fostamatinib) Warm Antibody AIHA. If these processes fail, however, autoantibodies—a product ofRead More. We designed KSI-301 with the goal to keep the disease under control for longer, aiming to dose as infrequently as every 3, 4, or. is a California-based biotech company. The acquisition adds two oral factor D inhibitors to treat rare diseases associated with the complement alternative pathway to Alexion's clinical-stage pipeline - danicopan (ACH-4471) and ACH-5228. Research groups have tried subunit vaccines repeatedly and failed. What Biotech Investors Need to Know. Investing in biotech R&D has yielded better returns than the pharma-industry average. We are a commercial stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and anti-infectives. Innovations and Developments. Imeglimin is the first orally-available anti-diabetes drug candidate that simultaneously targets all three key organs of diabetes, which includes the pancreas, liver, and muscles. Therefore, market analyst's reports on company pipelines are an important investment tool. Multiple tumor settings. Idorsia's development compounds target a number of different diseases. BARCELONA, Spain, Jan. Key 2020 Events. Amgen has become the latest biopharma to try to figure out the hit it may take to its pipeline timings amid the COVID-19 pandemic. While our motivation is simple, the science that goes into creating a lung surfactant that resembles the real thing is a little more complicated. Download CRISPR Therapeutics Corporate Presentation. The mysterious coronavirus outbreak in the Chinese city Wuhan, now termed as COVID-19, and its fast spread to many other countries, endangers thousands of lives. Validation and Capital from Deal Enables XBiotech to Vigorously Advance anti-IL-1⍺ Antibody Program, Fuel Pipeline. Lysosomal Function. Meg Tirrell @megtirrell. LEARN MORE ABOUT OUR TECHNOLOGIES. The preclinical, clinical and production process of gp-ASIT+ TM for. Greenovation's development pipeline as of September, 2017 Moss-aGal and Moss-GAA are subsitutes for human lysosomal enzymes, developed for enzyme replacement therapy (ERT), i. Over 1 million valuation calculations to date. The biotech sector was in focus with new drug approvals, acquisitions and regular pipeline updates from quite a few companies. biotech-pipeline. Our lead program, mirvetuximab soravtansine, is a first-in-class ADC in Phase 3 development for platinum-resistant ovarian cancer and we have a number of ADCs in development in our clinical and early stage pipelines. com View map and directions. ReviveMed's Pipeline of Metabolic Diseases We are initially focused on discovering therapeutics for alcoholic and non-alcoholic fatty liver diseases. Imeglimin is the first orally-available anti-diabetes drug candidate that simultaneously targets all three key organs of diabetes, which includes the pancreas, liver, and muscles. OUR PIPELINE & SCIENCE Led by scientists with an elite level track record in biomedical research, we are advancing a pipeline of novel and proprietary drug candidates by applying our unique platform technologies. The table illustrates our discovery programs and opportunities as of January 2020. All content is Derek's own, and he does not in any way speak for his employer. Sentien's technology has now been tested in numerous preclinical models and, in each case. Legend Biotech sees the promise of allogeneic cell therapy and its potential benefits. Passion for Discovery pipeline. Now SIRION offers one of the world’s most comprehensive viral vector technology platforms based on lenti-, adeno-, and adeno-associated viruses which expedites gene therapy research and advances. Bharat Biotech is a pioneering biotechnology company known for its world-class R&D and manufacturing capabilities. Food and Drug Administration (FDA) in 2000. The programs in our broader Synerlytic™ platform serve as the backbone of Virogin’s continued R&D of targeted and improved cancer. The word pipeline in biotech companies generally refers to the stages of clinical trials. Based on innovative material science and composition-of-matter patents, Xbio ™ Technology has limitless potential to have a far-reaching and positive impact across all human and animal health care and support the global drive to reduce the threat of antimicrobial resistance caused by biofilms. Clinical Pipeline. Marketwired February 15, 2017, 2:00 PM UTC. 325 East Middlefield Road Mountain View, CA 94043 (650) 965-7873 [email protected] Autoimmune diseases are the result of an individual's immune system attacking its own healthy cells and tissue. These five biotech stocks to buy are about to put out promising new drugs, with more products in the works. The steady growing, ~$4B* Japanese diabetes market offers a unique value creation opportunity. Quite a few companies came out with important news this week. Our pipeline programs are in Fibrosis (Collagen type I translation inhibitors), RSV (inhibiting the production of viral proteins by host cell ribosomes), Oncology (C-Myc translation inhibitors), Huntington’s Disease (monitoring mutant Huntingtin translation pausing) and Repeat Associated Diseases (translation malfunctions). Phone: +1 (212) 967-4077. We are building the foundation to become a leading biopharmaceutical company dedicated to developing and commercializing innovative therapies in the CNS area. If you would like to access information about Juno and its products and pipeline, please click here. At Reata Pharmaceuticals, our mission is to develop innovative therapies that change patients’ lives for the better. Cidara is pursuing an infectious disease-focused development strategy intended to transform standards of care and save lives. ASIT biotech's lead product is gp-ASIT+ TM for grass pollen rhinitis is currently in Phase III development. Our lead program, VG161, has completed the IND-enabling phase, in preparation for clinical development. Building a Pipeline of Immunotherapies. Biotech companies are only as good as their pipeline. Get Marker News Delivered To Your Inbox. Currently, a year-long course of pegylated interferon-alpha is the best available curative therapy and it has a low functional cure rate of approximately 3-7%. Our areas of focus are a result of many years of experience and a deep understanding of industry dynamics and the leadership positions that the principals have established in these areas. Expanding the pipeline beyond RUCONEST®: With validation secured from the approval of the first product from our transgenic platform, we will now seek to initiate new projects on this platform. Our Focus on Patients. GY Highland Biotech LLC The Best Protection is Early Detection. As a reflection of our commitment and as a service to the community we are pleased to provide here the pipeline of epilepsy therapies in various stages of development. PDS Biotech's pipeline combines Versamune PDS Biotech is developing PDS0103 for the treatment of ovarian, breast, colorectal and lung cancers. Moleculin Biotech, Inc. Our lead program, mirvetuximab soravtansine, is a first-in-class ADC in Phase 3 development for platinum-resistant ovarian cancer and we have a number of ADCs in development in our clinical and early stage pipelines. ADZ4 combines the virus backbone of ADZ1 with the expression of CD137 ligand (4-1BBL). Justice Action Bulletin: Dakota pipeline, drones, food biotech criminal conspiracy to block Energy Transfer Partners' Dakota Access Pipeline, including encouraging vandalism in Wapello and. IL-15 is a cytokine mainly expressed by monocytes, dendritic cells and epithelial cells. Research groups have tried subunit vaccines repeatedly and failed. We're focused on creating the cutting-edge therapies and technologies that can change life for the better. Our pipeline of investigational immunotherapies features our costimulatory technology designed to target and treat a wide. Greenovation's development pipeline as of September, 2017 Moss-aGal and Moss-GAA are subsitutes for human lysosomal enzymes, developed for enzyme replacement therapy (ERT), i. Immuno-oncology. Thermosetting, prolonged-release antibiotic formulation aims to help treat once and done. Mersana’s innovative platforms are a highly efficient product engine that is building a robust discovery pipeline for us and our partners. Our pipeline includes immunotherapies and other targeted biologics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases. Atreca, Inc. Our mission is to deliver affordable, safe and high-quality vaccines and bio-therapeutics that help people prevail over diseases. Spinocerebellar Ataxia Program SCA is a genetic, degenerative neurological condition that affects approximately. This site uses cookies as described in our Cookie Policy Please click the. Pipeline Developing the next generation of oncolytic immunotherapy. Derek Lowe's commentary on drug discovery and the pharma industry. For this reason, several analysts believe this biotech’s future is only going to get brighter. is a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with various conditions. Learn about AWS Cloud services and solutions for pharma and biotech to improve efficiency and accelerate your pipeline, from basic research through commercialization models. Virogin is dedicated to bringing the next generation of immuno-oncolytic therapeutics to the clinic through our robust pipeline. Below, we'll take a look at the top 3 stocks in the biotechnology sector for the second quarter of 2020 in terms of the best value, the fastest earnings growth, and the most momentum. Immuno-Oncology. AXIM Biotech Offers the Broadest Pipeline in the Cannabis Industry -- SECFilings. For the benefit of patients. Based on its strong pipeline of assets targeting TGF- β, Wall Street has high hopes for this biotech, which IPO’d only a month ago. Spinocerebellar Ataxia Program SCA is a genetic, degenerative neurological condition that affects approximately. Learn about Alnylam's pipeline of investigational RNAi therapeutics and how the company is leading the translation of RNAi into a new class of innovative medicines to treat a variety of conditions. February 10, 2020. February 18, 2020. Our Pipeline. Rezafungin Prophylaxis (IV) Candida, PCP and Aspergillus in alloBMT. Be among the early investors in the new type of device that experts say could impact. At its simplest, biotechnology is technology based on biology - biotechnology harnesses cellular and biomolecular processes to develop technologies and products that help improve our lives and the health of our planet. Atreca, Inc. 2100 Wharton St. Biotechs are poised to see the light at the tunnel’s end for their products, following what has been — for most — a 10-to-15 year journey from discovery to approval. Krystal Biotech, Inc. Download PDF. Pipeline Navitor is developing small molecule drugs that selectively target the activation of mTORC1 to treat a range of diseases. Add a Comment. We aim to become a fully-integrated biotechnology company bringing transformative medicines to people with cancer. ARWR Due Diligence. Please click on a Program in pipeline image below for more information. Till date. How does such a small biotech build such a large pipeline? Ligand markets technology that helps other biopharmaceutical companies develop drugs more effectively. our pipeline. We have used the biological processes of microorganisms for more than 6,000 years to make useful…. Asthma is now recognized as a heterogeneous disease with two predominant subtypes categorized by the degree of T h 2-associated inflammation present in the airways. Investing in biotech R&D has yielded better returns than the pharma-industry average. Maverick Therapeutics is pioneering the next generation of redirected T-cell targeted immunotherapies. Besides having "one of the deepest product pipelines in the biotech industry," Celgene's $700 million in cash "gives it a great deal of flexibility with regards to making acquisitions and/or naming. ONY Biotech: Treatments for premature babies. Galecto Biotech has successfully completed its phase Ib/IIa clinical trial of TD139, the biotech company’s new drug developed for patients suffering from Idiopathic Pulmonary Fibrosis. Product Pipeline. 2019 Therachon was acquired by Pfizer. Phase 1 Phase in progress. Hear from actual Atrial Fibrillation (AFib) patients: “The longer you stay in AFib, the harder it is to get off of AFib. Now SIRION offers one of the world’s most comprehensive viral vector technology platforms based on lenti-, adeno-, and adeno-associated viruses which expedites gene therapy research and advances. X4's pipeline is comprised of first-in-class, oral, small molecule antagonists of chemokine receptor CXCR4, which have the potential to treat a broad range of rare diseases, including primary immunodeficiencies (PIs) and cancer. IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. Legend Biotech is a multinational biopharmaceutical company focused on discovering and developing cutting-edge cell-based therapies with the ultimate goal of changing the way life-threatening diseases are treated. BNT111 is developed for the treatment of advanced melanoma in patients with metastatic tumors and as an adjuvant treatment after tumor resection. The product candidates in the Merus pipeline are based on the Biclonics ® format (full length human IgG antibodies). a 50%-plus share of sales, or companies with. Potential Indication. The first indications will be multiple sclerosis (MS). He describes the main development pipeline of SOM Biotech, and outline the expertise of its team. PDS0201 combines the utility of the Versamune ® platform with a mix of influenza antigens including conserved regions of the virus. We are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products and a portfolio of central nervous system, or CNS, product candidates. Biotech companies are only as good as their pipeline. Download PDF. Here we present three non-cancer therapeutic areas wherein pipeline developments are expected to garner a lot of interest in 2020. GECCO offers a unique collection of cofactors. ( Source ). Although there are still a few days left for the year to end, 2017 has turned out to be pretty good for the pharma and biotech sector where FDA approvals are concerned. Gilead is advancing a pipeline of cancer therapies in the areas of cell therapy, immuno-oncology and targeted therapies. Window of Opportunity Study Preclinical Phase complete. SMSbiotech Product Pipeline. Clear All Selected. Our strategy employs the unique attributes of our proprietary bispecific antibodies and our patented screening technologies to engage and harness the power of the immune system to kill tumor cells. Spanish Biotech Pipelines. While the bigwigs did not come out with much updates, pipeline and regulatory updates took. Immuno-oncology. Santen Global Pipeline. Moderna is working to create mRNA medicines for a wide range of diseases and conditions. Click to read more on JHL1152 (Ipilimumab). Learn More. Scientific Publications. Growth of the Pipeline. We are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products and a portfolio of central nervous system, or CNS, product candidates. Our pipeline programs are in Fibrosis (Collagen type I translation inhibitors), RSV (inhibiting the production of viral proteins by host cell ribosomes), Oncology (C-Myc translation inhibitors), Huntington's Disease (monitoring mutant Huntingtin translation pausing) and Repeat Associated Diseases (translation malfunctions). Lysosomal Function. [email protected] So far SOTIO has sponsored 14 clinical trials. , our leading cell therapy pipeline now includes investigational cell therapies and next-generation technologies for a range of hematologic malignancies and solid tumors. LENTIGLOBIN TM PRODUCT CANDIDATE FOR TRANSFUSION-DEPENDENT β‑THALASSEMIA (TDT) TDT Non-β0/β0 genotypes (Northstar-2, HGB-207) TDT β0/β0 genotypes (Northstar-3, HGB-212) LENTIGLOBIN TM PRODUCT CANDIDATE FOR SICKLE CELL DISEASE (SCD) Planned: SCD (HGB-210) BCL11A shRNA (mir) 1. At least in terms of investing. Status of selected key development programs as of February 25, 2020. Our pipeline of investigational immunotherapies features our costimulatory technology designed to target and treat a wide. Isis Pharmaceuticals: 'The Best Pipeline in Biotech,' Potential Takeover Target Isis Pharmaceuticals (ISIS) met with investors yesterday--and they must have liked what they heard. Pipeline Biotech offers a full set of mathematical pharmacokinetic and pharmacodynamic (PK/PD) modeling services as integrated support for clients' in vivo studies. Immunocore is a leading T Cell Receptor (TCR) biotechnology company focused on delivering first-in-class biological therapies that have the potential to transform the lives of people with serious diseases. From modest beginnings 20 years ago, Neem Biotech has come of age. Pipeline Expansion. CUREform. Iduronate 2-sulfatase. In this quarter’s Fast Money Watchlist report, I’m going to tell you about a cell therapy company that’s in the final stage before an FDA decision, with a platform that might prove to be useful in treating coronavirus itself. The most heavily invested area of drug development is in the search for new agents to treat cancer. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Phase 3 Phase not started. Phase 2 Phase in progress. Pipeline We employ biologic and small molecule-based approaches that are designed to enhance the ability of the patient’s own immune system to detect and destroy cancer cells. Prothena Corporation plc 77 Sir John Rogerson’s Quay, Block C Grand Canal Docklands Dublin 2, D02 T804, Ireland TEL +353 1 236 2500 FAX +353 1 902 3510 EMAIL [email protected] Rapidly advancing pipeline. In 2015, the first two Oncology products were commercialized in India - Lupifil and Lupifil-P (biosimilars for molecules Filgrastim and Peg-Filgrastim). The FDA's flexibility and focus on marketplace. We seek to develop targeted therapies to better serve patients and ensure the right drug gets to the right patient. Discovering New Compounds to be Tested as Therapeutics in a Wide Range of Clinical Applications. #N#Products in development. We are proud of the advancements we've made in pioneering new vaccines and therapeutics that may have the potential to treat rare diseases like. All content is Derek’s own, and he does not in any way speak for his employer. MorphoSys mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. We are presently devoting most of our resources to the commercialization or development of our four most advanced drug programs:. Immune-mediated Diseases. A biopharma worker. Get a brief summary of the day’s biotech price and volume movers and accompanying news. As of July 2005, the company does not have a marketed product, though it has three therapeutics in its drug discovery pipeline as shown in the table below. Pharmaceutical companies usually have a number of compounds in their pipelines. Our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules. Spinocerebellar Ataxia Program SCA is a genetic, degenerative neurological condition that affects approximately. Sentien Biotechnologies is a clinical-stage company developing a first-in-class extracorporeal bioreactor to treat patients with systemic inflammatory diseases. From clinical strategy to commercial success IQVIA Biotech provides flexible, tailored, integrated clinical and commercial solutions designed to help smaller biotech companies move forward in their effort to get treatments to patients – from defining the plan for their asset, to trial design and implementation, through launch and commercialization – all while delivering compelling results. We also have a discovery-stage small molecule STING agonist program. Working every day as if people’s lives depend on it, CSL’s R&D fuels the company’s sustainable growth by advancing world-class science, technology and collaboration. 4-1BB agonist ligand is a powerful costimulatory molecule which induces activating signals in CD8+ T cells and natural killer cells, resulting in increased pro-inflammatory cytokine secretion, and cytolytic function, enhancing immune responses directed to tumors. We are poised to create several molecules from the O. Biotech companies are only as good as their pipeline. - Product Pipeline Review - 2015 Hawaii Biotech, Inc. Gritstone is building a pipeline of immunotherapy product candidates for patients with solid tumors. Our goal is to be an industry leader in each of these therapeutic areas and enhance and extend the lives of patients suffering from such diseases. Pipeline; We are a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. As one of the world’s most renowned companies for contract development and manufacturing, Lonza Pharma & Biotech is recognized for our reliable, high-quality services, our global capacity, our innovative technology platforms, and our extensive experience. Bharat Biotech is a pioneering biotechnology company known for its world-class R&D and manufacturing capabilities. The $50 million payment is a small price to pay to help boost its paltry pipeline. [email protected] Innovative Diagnostic Pipeline Adding new pages to the story of the adaptive immune system At Adaptive, we’re investing in the continued development of immune-driven medicine products, which add new meaning to the stories every patient’s immune system has to tell. ADZ4 combines the virus backbone of ADZ1 with the expression of CD137 ligand (4-1BBL). Preclinical development of hdm-ASIT+ TM (for house dust mite rhinitis) and pnt-ASIT+ TM (for peanut allergy) should be available in H1 2020. Myotonic Dystrophy is a highly disabling multisystemic disease with no cure available. Phase 1 Phase in progress. PCI Biotech is leveraging PCI (fimaporfin) in three distinct areas: Pipeline. Board of Directors. Kineta is developing a focused pipeline of novel first-in-class immunotherapies in therapeutic areas with significant unmet medical needs. Our AlloCAR T portfolio includes rights to 15 preclinical CAR T cell therapy targets licensed from Cellectis and U. Investing in biotech R&D has yielded better returns than the pharma-industry average. How does such a small biotech build such a large pipeline? Ligand markets technology that helps other biopharmaceutical companies develop drugs more effectively. Passion for Discovery pipeline. Gossamer Bio. Our first product candidate, GRANITE is a personalized neoantigen-based immunotherapy. Our current clinical studies are designed to further evaluate the safety and efficacy of our sPLA2 inhibitor technology. These products target markets with over $20 billion in annual sales and have clearly defined clinical development paths. Our pipeline of key proprietary products includes a late-stage drug candidate for the treatment of schizophrenia and the treatment of bipolar I disorder, and an early-stage drug candidate in immuno-oncology. 11975 El Camino Real, Suite 300 San Diego, CA 92130 T (858) 222-8041 F (858) 436-8155. Aducanumab isn’t the only one. More than 130 sponsors have repeatedly used our services during the last ten years. Editing cells inside the body to treat genetically-defined diseases. 188 East Blaine Street Suite 200 Seattle, WA 98102 206-788-4545. While our initial focus is in neurology, our stereopure chemistry platform may unlock the potential for transformative therapies in many therapeutic areas. And thanks to the commitment of the R&D unit, different successful products were developed in these therapeutic areas. All content is Derek’s own, and he does not in any way speak for his employer. As of July 2005, the company does not have a marketed product, though it has three therapeutics in its drug discovery pipeline as shown in the table below. ) on ARWR, Aug 2019 - $100. 4020 Fax: 510. Genetically defined cancers. Few biotech companies have developed a broad portfolio of experimental products as quickly as Icos has since it went into business in 1990. Rezafungin Treatment (IV) Candidemia and Invasive Candidiasis. Innovating for Our Patients. Immune Tolerance. Previously Juvenescence AI limited, Generait was founded in July 2017, a partnership between Juvenescence and the leading AI drug discovery company Insilico Medicine, Inc, providing a vehicle to develop promising candidates identified using its end-to-end automated drug discovery pipeline through to clinical proof of concept. 3 Biotech Stocks With Potential In Their Pipelines The increase of the aging population presents immense opportunities for bio-pharmaceutical companies to develop candidates to treat global ailments. Rezafungin Prophylaxis (IV) Candida, PCP and Aspergillus in alloBMT. Alopexx Pipeline. [email protected] For some biotech companies, money from China has breathed new life into experimental drugs or devices that lost priority inside company pipelines for various reasons. The FDA's flexibility and focus on marketplace. A biosimilar is a biologic medical drug that is almost an identical copy of an innovator product that is manufactured by a different company. Our pipeline programs are in Fibrosis (Collagen type I translation inhibitors), RSV (inhibiting the production of viral proteins by host cell ribosomes), Oncology (C-Myc translation inhibitors), Huntington’s Disease (monitoring mutant Huntingtin translation pausing) and Repeat Associated Diseases (translation malfunctions). Allogeneic or Autologous TAC-AAV Undisclosed Genetic Diseases. The Company’s lead candidate is tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, which AVEO is seeking to develop and commercialize in North America as a treatment for […]. We are focused on the development and commercialization of innovative therapeutics for the treatment of cancer. With a focus on minimising disease burden and antimicrobial resistance, our ethos is to do things differently. Gilead is advancing a pipeline of cancer therapies in the areas of cell therapy, immuno-oncology and targeted therapies.